Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Pearls in Skin of Color
Description
Andrew Alexis presents a discussion on clinical and therapeutic pearls specific to patients with skin of color, focusing on the management of inflammatory skin disorders such as psoriasis and atopic dermatitis. He emphasizes the unique challenges faced by these patients, particularly regarding additional concerns like pigmentary changes accompanying chronic inflammatory conditions. Alexis illustrates his points with a detailed case study of a patient with severe psoriasis, highlighting the importance of persistent treatment over an extended period to achieve desired outcomes, not only for the primary inflammation but also for associated hyperpigmentation. He also discusses recent data on the efficacy of biologics like secukinumab and guselkumab in improving symptoms and quality of life, explicitly noting the significance of monitoring pigmentary changes in such treatments. Furthermore, he addresses the potential for misdiagnosis in skin conditions that may mimic others, such as sarcoidosis or scleroderma, reinforcing the need for comprehensive evaluations, including biopsies when necessary. Throughout the talk, Alexis stresses the importance of clinician awareness and thorough examinations to manage and diagnose skin conditions in darker-skinned patients accurately, enhancing their treatment experience and outcomes.
View moreConclusions
- Inflammatory skin disorders in patients with skin of color can lead to both primary disease symptoms and pigmentary changes.
- Management of chronic inflammatory skin conditions is a long-term process requiring consistent treatment.
- Systemic therapies like secukinumab and guselkumab are effective for treating psoriasis in darker-skinned individuals, leading to improvements in both skin condition and quality of life.
- Significant improvements in post-inflammatory pigment changes can be observed with effective treatment, but may take several months to years.
- Patients with skin of color experience a unique response to treatment due to pigmentation and erythema characteristics.
- Atopic dermatitis treatments, such as dupilumab and lebrikizumab, show promise in managing symptoms and pigmentary changes in darker-skinned populations.
- Accurate diagnosis is crucial, as conditions resembling common skin disorders can require entirely different management approaches.
- Thorough skin examinations and patient histories are essential for identifying underlying conditions that may mimic pigmentation disorders.
- El-Kashlan N, Cices A, Kaufman B, Rosa JCD, Sanabria-Gonzalez I, Khattri S, Alexis A. J Drugs Dermatol. 2024 Aug 1;23(8):600-606
- Alexis A et al. Poster at the 2024 Fall Clinical Dermatology Conference
- Obijiofor C et al. Int J Womens Dermatol. 2024 Sep 13;10(3):e181
- Ntiri M, Nazarian A, Magro C, Alexis AF JAAD Case Reports 2024;49:135-9
- Mora Hurtado AC, Elbuluk N. J Drugs Dermatol 2025; 24(2):203-204
- La Placa M. J Am Acad Dermatol 2008 Nov;59(5 Suppl):S126
- Henderson CL et al. J Am Acad Dermatol 2008;59:143